Abbott (NYSE:ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million.
Abbott Reported Earlier It Will Acquire Cardiovascular Systems For $20/Share
Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
Related Posts
Piper Sandler Downgrades Ardelyx to Neutral, Lowers Price Target to $4
Piper Sandler analyst Christopher Raymond downgrades Ardelyx (NASDAQ:ARDX) from Overweight to Neutral and lowers the price target from $14 to $4.
Accelerate Diagnostics Priced 17.5M Share Public Offering of Common Stock @$2/Share
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share.
What Does Okta’s Debt Look Like?
Shares of Okta Inc. (NASDAQ:OKTA) increased by 35.11% in the past three months. Before having a look at the importance of debt, let's look at how much debt Okta has.